[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hormonal-response\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hormonal-response":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100650334","comparison-of-hormonal-response-to-a-mixed-meal-tolerance-test-after-laparoscopic-roux-en-y-gastric-bypass-versus-laparoscopic-sleeve-gastrectomy-with-duodenojejunal-bypass-in-patients-with-super-morbid-obesity-100650334",false,"NCT07747779","Comparison of Hormonal Response to a Mixed-Meal Tolerance Test After Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy With Duodenojejunal Bypass in Patients With Super Morbid Obesity","Comparison of Hormonal Response to a Mixed-Meal Tolerance Test After Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy With Duodenojejunal Bypass in Patients With Super Morbid Obesity: A Prospective Single-Center Non-Inferiority Randomized Clinical Trial","CU BYPASS-DJB","Inclusion Criteria:\n\n* Patients with an indication for bariatric surgery\n* BMI 50-60 kg\u002Fm2\n* Patients who are motivated to lose weight but have not achieved successful weight reduction despite optimal medical therapy and exercise under physician supervision\n\nExclusion Criteria:\n\n* Patients with diabetes mellitus\n* Patients with severe comorbid conditions that contraindicate surgery, such as advanced heart disease or chronic kidney failure\n* Patients with a history of previous bariatric surgery\n* Patients with gastroesophageal reflux disease refractory to medical therapy, large hiatal hernia, or endoscopic findings of reflux esophagitis grade C or D, or Barrett esophagus\n* Patients with psychiatric disorders that impair eating behavior control\n* Patients with a history of pancreatitis, pancreatic disease, or inflammatory bowel disease\n* Patients who have used steroids or GLP-1 receptor agonists within the past 2 months","ALL","18 Years","60 Years",{"count":21,"type":22},32,"ESTIMATED","INTERVENTIONAL",[25],"NA","Obesity is a major global health problem. Bariatric surgery is the most effective treatment, leading to substantial weight loss and improvement in obesity-related comorbidities. The most commonly performed procedures are Laparoscopic Roux-en-Y gastric bypass (LRYGB) and Laparoscopic sleeve gastrectomy (LSG). LRYGB is typically selected for patients with a BMI exceeding 50 kg\u002Fm2. Recently, LSG with duodenojejunal bypass (LSG-DJB) has been introduced. To date, no randomized controlled trial has compared LRYGB and LSG-DJB in patients with super morbid obesity, particularly regarding postoperative hormonal responses. This study aims to address this gap. If LSG-DJB results in a lower incidence of post-bariatric hypoglycemia than LRYGB, it would support its clinical benefit. Evaluation of GLP-1, GIP, glucagon, and insulin responses will clarify mechanisms underlying weight loss and postprandial glycemic changes.",[28,29,30],"Bariatric Surgery","Hormonal Response","Post Bariatric Hypoglycemia",[28,29,32],"Post bariatric hypoglycemia","RECRUITING","2026-08-04",{"date":36,"type":37},"2026-08-06","ACTUAL",{"date":39,"type":37},"2024-08-08",{"date":41,"type":22},"2027-07-31",{"name":43,"class":44},"Chulalongkorn University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":66,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":45},"100628788","phase-4-exogenous-progesterone-as-ovulation-trigger-100628788","NCT07466199","Exogenous Progesterone as Ovulation Trigger","Exogenous Progesterone as Ovulation Trigger - a Pilot Study","PRO-TRIGGER","Inclusion Criteria:\n\n* Informed Consent Form dated and signed correctly prior to the performance of any study procedure.\n* Oocyte donors aged \\>17 and \\\u003C34 years old in the moment of the recruitment.\n* Patients with regular menstrual cycles (between 25 to 35 days long).\n* Generally healthy women with no history of endocrine disorders (e.g., polycystic ovary syndrome (PCOS) or significant systemic disease).\n* Body Mass Index (BMI) between 18.5 and 28.\n\nExclusion Criteria:\n\n* Presence of ovarian cyst(s) detected on the baseline (initial) ultrasound examination.\n* Untreated endocrine conditions (polycystic ovary syndrome (PCOS), uncontrolled thyroid dysfunction and hyperprolactinemia).\n* Hypogonadotropic or hypergonadotropic hypogonadism.\n* Known hypersensitivity or clinical contraindication to the administration of vaginal progesterone or its excipients. This includes, but is not limited to: active deep vein thrombosis or thromboembolic disorders, known or suspected estrogen- or progesterone-dependent neoplasia, undiagnosed abnormal genital bleeding, porphyria, or severe hepatic dysfunction. Additionally, patients with anatomical abnormalities of the vagina that preclude the proper insertion or absorption of the vaginal insert are excluded.\n* Any condition contraindicating vaginal ultrasound and\u002For vaginal oocyte retrieval.These include: active pelvic inflammatory disease (PID), acute vaginal or cervical infection, or presence of pelvic malignancies. Patients with significant anatomical distortions or vascular anomalies in the pelvic region that, in the investigator's opinion, would make oocyte retrieval technically unfeasible or pose an unacceptable risk of hemorrhage or injury to adjacent organs, are also excluded.\n* Use of hormonal contraceptives (oral, patch, or ring) or GnRH analogues within the month preceding the study. Note: Participants who have discontinued these or other prohibited medications for a period of at least 30 days are eligible for rescreening starting at Visit 1.\n* Participation in any other ongoing clinical trial or use of investigational drugs within the last 30 days.","FEMALE","33 Years",{"count":57,"type":22},10,[59],"PHASE4","The goal of this clinical trial is to learn whether the sudden administration of vaginal micronized progesterone during the late follicular phase can trigger an LH surge and reactivation of oocyte meiosis in healthy oocyte donors aged 18 to 33 undergoing a mild ovarian stimulation cycle. The main question it aims to answer is:\n\n* Does progesterone administered in the late follicular phase induce an LH surge and subsequent oocyte meiosis reactivation?\n\nParticipants will:\n\n* Undergo a mild ovarian stimulation with 75 IU of follitropn alfa\n* Start vaginal micronized progesterone (400 mg every 12 hours) once at least one follicle reaches 15 mm\n* Have blood samples collected to measure hormone levels before and after progesterone administration\n* Undergo oocyte retrieval 35-36 hours after the progesterone trigger\n\nThis is a low-intervention, single-center pilot study including approximately 10 oocyte donors.",[62,63,64,65,29],"Ovulation","Ovarian Function","Assisted Reproductive Treatments","Oocyte Maturation",[67,68,69,65,70,71,72,73,74,75],"Trigger","Oocyte Donation","Progesterone","Luteinizing Hormone","LH Surge","Oocyte Retrieval","Oocyte Meiosis","Late Follicular Phase","Endocrinological profile","NOT_YET_RECRUITING","2026-06-02",{"date":79,"type":37},"2026-06-04",{"date":81,"type":22},"2026-07",{"date":83,"type":22},"2026-08",{"name":85,"class":86},"Instituto Valenciano de Infertilidade de Lisboa","NETWORK"]